Movers and SHAKERS
Lineage Cell Therapeutics (LCTX)
OpRegen Data Update Adds To Evidence of Efficacy
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Additional Data Released: Lineage Cell released additional data from its Phase 1/2a clinical trial testing OpRegen, its retinal pigment epithelium (RPE) cell transplant. The full data presentation is scheduled for the Annual Scientific Meeting of the Retina Society on September 30. The new data was from patients who have been followed for at least 9 months from their treatment and shows both durable improvements in function and cellular structure. We believe it supports our expectations for product efficacy and our investment thesis for the stock.
Study Design. The Phase 1/2a trial tests OpRegen, an allogenic RPE cell transplant product for dry age-related macular degeneration (dry AMD). The trial has a total of 24 patients, with three cohorts totaling 12 patients to demonstrate safety, followed by a fourth cohort of 12 patients to demonstrate efficacy. Patients in Cohort 4 had dry AMD with areas of geographic atrophy (GA) where RPE cells ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.